COMMUNICATIONS
Table 1. In vitro antitumor activity[a] of complex 6.
[7] Compound 2 was prepared from 1,3-dibromo-2-propanol by reaction
with NaN3 in DMF.
Cell line
Tumor of origin
MED[b] [mm]
Cisplatin
[8] 6: 1H NMR (500 MHz, D2O): d 4.39 (d, J(H1,H2) 8.0 Hz, 1H;
H1), 4.23 (m, 1H; CH(CH2NH2)2), 3.70 (dd, J(H6a,H6b) 12.5,
J(H5,H6a) 2.0 Hz, 1H; H6a), 3.55 (dd, J(H6a,H6b) 12.5,
J(H5,H6b) 5.0 Hz, 1H; H6b), 3.34 ± 3.23 (m, 3H; H3, H4, H5),
3.17 (dd, J(H2,H3) 9.5, J(H1,H2) 8.0 Hz, 1H; H2), 2.89 ± 2.84,
2.72 ± 2.65 (2m, 2 Â 2H; CH(CH2NH2)2); 13C NMR (125 MHz, D2O):
d 102.2 (C1), 76.5, 76.2 (C3, C5), 74.1 (CH(CH2NH2)2), 73.7 (C2),
70.1 (C4), 61.2 (C6), 46.2, 45.1 (CH(CH2NH2)2).
6
A2780S[c]
A2780cP[c]
MeWo[d]
ovarian
ovarian
melanoma
2.5
112
11.2
3.3
36
8
[a] Cytotoxicity was assessed by clonogenic survival assay as described.[12]
[b] Median effect dose. [c] A2780S and its cisplatin-resistant variant,
A2780cP, were obtained from Dr. Marshal Sklar (University of Miami)
and maintained in Paul G. Braunschweigerꢀs laboratory. [d] Obtained from
Dr. Jorgen Fogh and maintained in Paul G. Braunschweigerꢀs laboratory.
[9] Crystal structure data (Bruker P4/CCD diffractometer) for 6 ´ 1.5H2O:
C9H23Cl2N2O7.5Pt, Mr 545.28, crystal dimensions 0.32Â 0.22Â
0.06 mm3, T 295(2) K, monoclinic, space group P21, a 690.390(10),
b 3174.58(6), c 809.74(2) pm, b 115.0650(10)8, Z 4, V
1.60758(6) nm3, 1calcd 2.253 gcm 3, MoKa radiation (l0 0.71073 ),
m 9.096 mm 1, 2q 2.56 ± 56.688; of 9952 reflections collected, 6498
were independent (R(int) 0.031); refinement method: full-matrix least
squares on F 2, 397 refined parameters, empirical absorption correction
(SADABS software, Tmin and Tmax undefined), GOF 1.008 (based on
F 2), R1 0.0383, wR2 0.0915 (s> 2s(I)), absolute structure parameter
0.007(8), residual electron density 2.559/3.782 e 3. The structure
was solved and refined with the programs SHELXS-93 and SHELXTL.
The hydrogen atoms were placed in their geometric positions (riding
model), except that no hydrogen atoms were placed in the solvent
molecules. Crystallographic data (excluding structure factors) for the
structure reported in this paper have been deposited with the Cam-
bridge Crystallographic Data Center as supplementary publication no.
CCDC-113805. Copies of the data can be obtained free of charge on
application to CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax:
(44)1223-336-033; e-mail: deposit@ccdc.cam.ac.uk).
should open new avenues to explore this important area of
cancer chemotherapy.
Moreover, complex 6 is, to the best of our knowledge, the
first example of a carbohydrate-containing transition metal
complex in which the carbohydrate moiety is not only
unprotected, but also unbound to the metal center.[6, 14] Such
complexes should be obtainable as single crystals, which can
then be used to determine the solid-state structure of intact
and unprotected carbohydrates.
Experimental Section
6: A mixture of 1 (2.2 g, 5.36 mmol), 2 (1.14 g, 8.0 mmol), and 4-
molecular sieves (3.5 g) was stirred under Ar for 1 h at RT in CH2Cl2
(50 mL), and HgBr2 (0.39 g, 1.07 mmol) and HgO (1.16 g, 5.36 mmol) were
added. After being stirred in the dark for 2 d, the mixture was filtered
through a layer of Celite. The filtrate was washed with aqueous NaHCO3
solution, dried, and concentrated. Chromatography of the residue in
[10] For examples, see reference [6].
[11] J. Wang, Y. L. Bennani, F. Belanger-Gariepy, S. Hanessian, Acta
Crystallogr. Sect. C 1991, 47, 1067 ± 1069, and references therein; see
also reference [6].
hexanes/ethyl acetate (1/1) on silica gel afforded
Compound 3 (0.78 g, 2.56 mmol) and a catalytic amount of NaOMe were
3 (1.59 g, 63%).
[12] P. G. Braunschweiger, V. S. Basrur, O. Santos, J. P. Perras, A. M.
Markoe, P. Houdek, J. G. Schwade, Biotherapy 1997, 10, 129 ± 137.
stirred in MeOH (30 mL) for 6 h at RT. The mixture was neutralized by
1
[13] Solubility of 6 in water: >20 mgmL at 258C.
addition of Dowex H ion-exchange resin and filtered, and Pd/C (60 mg)
[14] Crystal structures of platinum(ii) complexes of unprotected carbohy-
drate diolates have been reported, but there the carbohydrates are
directly bound to platinum, and the complexes are not used in
biological study. For examples, see a) A. Appelt, A. C. Willis, S. B.
Wild, J. Chem. Soc. Chem. Commun. 1988, 938 ± 940; b) M. A.
Andrews, G. L. Gould, Organometallics 1991, 10, 387 ± 389; c) M. A.
Andrews, E. J. Voss, G. L. Gould, W. T. Klooster, T. F. Koetzle, J. Am.
Chem. Soc. 1994, 116, 5730 ± 5740.
was added. After being stirred under H2 (35 psi) for 8 h, the mixture was
filtered through a layer of Celite, and the filtrate concentrated. The residue
was redissolved in H2O and lyophilized to give 4 (0.4 g, 96%). Compound 4
(0.18 g, 0.71 mmol) and 5 (0.3 g, 0.71 mmol) were stirred in H2O (10 mL)
for 2 d at RT, and concentrated. Chromatography of the residue on a gel
filtration column with Bio-gel P2 resin afforded 6 (0.28 g, 75%).
Received: January 13, 1999 [Z12900IE]
German version: Angew. Chem. 1999, 111, 1882 ± 1884
Keywords: antitumor agents
´ bioinorganic chemistry ´
carbohydrates ´ N ligands ´ platinum
[1] B. Rosenberg, L. VanCamp, J. E. Trosko, V. H. Mansour, Nature
(London) 1969, 222, 385 ± 386.
Mixed Crossed Aldol Condensation between
Conjugated Esters and Aldehydes Using
Aluminum Tris(2,6-diphenylphenoxide)
[2] a) Metal Complexes in Cancer Chemotherapy (Ed.: B. K. Keppler),
VCH, Weinheim, 1993; b) Molecular Aspects of Anticancer DrugÐ
DNA Interactions, Vol. 1 (Eds.: S. Neidle, M. Waring), Macmillian,
Basingstoke, 1993; c) J. Reedijk, Chem. Commun. 1996, 801 ± 806.
[3] Reviews: a) A. Pasini; F. Zunino, Angew. Chem. 1987, 99, 632 ± 642;
Angew. Chem. Int. Ed. Engl. 1987, 26, 615 ± 624; b) R. B. Weiss, M. C.
Christian, Drugs 1993, 46, 360 ± 377.
Susumu Saito, Masahito Shiozawa, and
Hisashi Yamamoto*
Crossed aldol condensation between two different carbonyl
compounds is one of the earliest and synthetically most
significant reactions for carbon ± carbon bond formation.[1]
[4] a) J. Reedijk, Inorg. Chim. Acta 1992, 198±200, 873±881, and references
therein; b) A. Iakovidis, N. Hadjiliadis, Coord. Chem. Rev. 1994, 135/
136, 17 ± 63, and references therein; c) K. F. Morris, L. E. Erickson,
B. V. Panajotova, D. W. Jiang, F. Ding, Inorg. Chem. 1997, 36, 601 ± 607.
[5] a) S. Hakamori, Annu. Rev. Biochem. 1981, 50, 733 ± 764; b) Y.-T. Li,
S.-C. Li, Adv. Carbohydr. Chem. Biochem. 1982, 40, 235.
[6] For examples of platinum(ii) complexes of diamino-dideoxy carbohy-
drates (coordination through the amino groups) as cisplatin analogues,
see a) T. Tsubomura, M. Ogawa, S. Yano, K. Kobayashi, T. Sakurai, S.
Yoshikawa, Inorg. Chem. 1990, 29, 2622 ± 2626; b) S. Hanessian, J. Y.
Gauthier, K. Okamoto, A. L. Beauchamp, T. Theophanides, Can. J.
Chem. 1993, 71, 880 ± 885; c) S. Hanessian, J.-G. Wang, Can. J. Chem.
1993, 71, 886 ± 895.
[*] Prof. Dr. H. Yamamoto, Dr. S. Saito, M. Shiozawa
Graduate School of Engineering, Nagoya University
CREST, Japan Science
and
Technology Corporation (JST)
Furo-cho, Chikusa
Nagoya 464-8603 (Japan)
Fax : ( 81)52-789-3222
Angew. Chem. Int. Ed. 1999, 38, No. 12
ꢀ WILEY-VCH Verlag GmbH, D-69451 Weinheim, 1999
1433-7851/99/3812-1769 $ 17.50+.50/0
1769